European Medicines Agency provides update on AstraZeneca vaccine: “The current situation is not unexpected”

“We remain firmly convinced that the benefits of the AstraZeneca vaccine in preventing Covid-19, with its associated risk of hospitalization and death, outweigh the risk of these side effects,” said the executive director of the ‘EMA Emer Cooke on a video conference.

The current situation, with concerns about AstraZeneca’s vaccine against the coronavirus, is “not unexpected,” Emer Cooke, director of the European Medicines Agency (EMA), said on Tuesday afternoon during a presentation. an online press point.

The Irishwoman tried to reassure, highlighting the evaluation work of her agency, which will pronounce this Thursday on the cases of thrombosis which have pushed several States to stop their use of the AstraZeneca vaccine.

“When we vaccinate millions of people, it is inevitable to have serious incidents or diseases that appear after vaccination,” Emer Cooke reminded reporters.

As indicated by the EMA last week, and again on Monday, its pharmacovigilance risk assessment committee (PRAC) is in the process of evaluating the cases of thrombosis which have been brought to its attention. A meeting is taking place on Tuesday, and the conclusions of this committee will be announced on Thursday.

“Our role is to assess” the incidents reported, to “determine if it is a coincidence or if it is a real side effect” of vaccination with this specific product, recalled the director of the EMA, who assures us that his agency takes things very seriously. For this specific case, the risk assessment committee has also joined forces with international experts as well as specialists in thromboembolic incidents, she emphasizes.

As the EMA has already pointed out, however, it considers that it is still beneficial to use the AstraZeneca vaccine. The appearance of blood clots is a priori no more frequent among vaccinated people than among the rest of the population, thousands of people suffering from thrombosis each year in the EU.

Add a Comment

Your email address will not be published. Required fields are marked *